Compare S&P Global Inc (SPGI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs State Street SPDR S&P Biotech ETF — how do they compare? S&P Global Inc trades at $421.78 (market cap $126.56B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: S&P Global Inc pays a 0.9% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, S&P Global Inc nearer its low. Which is the better fit depends on your goals.
| SPGI | XBI | |
|---|---|---|
Market Cap | $126.56B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $522.21 | $169.55 |
52-Week Low | $370.42 | $93.43 |
Enterprise Value | $138.05B | — |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPGI trades at $429.31, down 3.2% over 24h, with a bullish technical signal and strong fundamentals including a 30.54% net income margin and consistent earnings beats. Recent news highlights strategic acquisitions and a focus on AI-resistant businesses, while analyst consensus remains strongly positive with an 85.7% buy rating.
Outlook is favorable due to high profitability and growth initiatives, but risks include rising debt levels and market sensitivity. The stock offers upside to the $523.20 consensus target, supported by institutional interest and dividend consistency.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
